Liu Z, Colovai A I, Tugulea S, Reed E F, Fisher P E, Mancini D, Rose E A, Cortesini R, Michler R E, Suciu-Foca N
College of Physicians and Surgeons of Columbia University, New York 10032, USA.
J Clin Invest. 1996 Sep 1;98(5):1150-7. doi: 10.1172/JCI118898.
To determine whether indirect allorecognition is involved in heart allograft rejection T cells obtained from peripheral blood and graft biopsy tissues were expanded in the presence of IL-2 and tested in limiting dilution analysis (LDA) for reactivity to synthetic peptides corresponding to the hypervariable regions of the mismatched HLA-DR antigen(s) of the donor. Serial studies of 32 patients showed that T cell reactivity to donor allopeptides was strongly associated with episodes of acute rejection. The frequency of allopeptide reactive T cells was 10-50-fold higher in the graft than in the periphery indicating that T cells activated via the indirect allorecognition pathway participate actively in acute allograft rejection. In recipients carrying a graft differing by two HLA-DR alleles the response appeared to target only one of the mismatched antigens of the donor. Indirect allorecognition was restricted by a single HLA-DR antigen of the host and directed against one immunodominant peptide of donor HLA-DR protein. However, intermolecular spreading was demonstrated in patients with multiple rejection episodes by showing that they develop allopeptide reactivity against the second HLA-DR antigen. These data imply that early treatment to suppress T cell responses through the indirect pathway of allorecognition, such as tolerance induction to the dominant donor determinant, may be required to prevent amplification and perpetuation of the rejection process.
为了确定间接同种异体识别是否参与心脏移植排斥反应,从外周血和移植活检组织中获取的T细胞在白细胞介素-2存在的情况下进行扩增,并在有限稀释分析(LDA)中检测其对与供体不匹配的HLA-DR抗原高变区相对应的合成肽的反应性。对32例患者的系列研究表明,T细胞对供体同种异体肽的反应性与急性排斥反应发作密切相关。移植组织中同种异体肽反应性T细胞的频率比外周血高10 - 50倍,这表明通过间接同种异体识别途径激活的T细胞积极参与急性移植排斥反应。在携带两个HLA-DR等位基因不同的移植受体中,反应似乎仅针对供体的一种不匹配抗原。间接同种异体识别受宿主单一HLA-DR抗原限制,并针对供体HLA-DR蛋白的一种免疫显性肽。然而,通过显示多次排斥反应发作的患者对第二种HLA-DR抗原产生同种异体肽反应性,证明了分子间扩散现象。这些数据表明,可能需要早期治疗以通过间接同种异体识别途径抑制T细胞反应,例如诱导对主要供体决定簇的耐受性,以防止排斥反应过程的放大和持续。